Compare CRTO & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | SPRY |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.6M | 761.6M |
| IPO Year | 2013 | 2020 |
| Metric | CRTO | SPRY |
|---|---|---|
| Price | $18.41 | $8.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $35.90 | ★ $40.00 |
| AVG Volume (30 Days) | 252.2K | ★ 1.5M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $2,296,692,000.00 | $84,278,000.00 |
| Revenue This Year | N/A | $90.76 |
| Revenue Next Year | $5.62 | $81.70 |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $16.15 | $6.66 |
| 52 Week High | $35.10 | $18.63 |
| Indicator | CRTO | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 44.33 |
| Support Level | $17.83 | $6.93 |
| Resistance Level | $19.79 | $10.44 |
| Average True Range (ATR) | 0.73 | 0.56 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 73.70 | 48.79 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.